[A randomized control clinical trial of Euruikang (docetaxel) in treatment of advanced non-small cell lung cancer (NSCLC)].
OBJECTIVE
Docetaxel is one of the major drugs for advanced non-small cell lung cancer (NSCLC) treatment in clinical use. It is reported that the response rate of docetaxel alone is about 20% and its major toxicity is myelosuppression. The study was to evaluate the efficacy and tolerability of docetaxel (made in Beijing) in the treatment of advanced NSCLC.


METHODS
77 patients were randomized into two groups. In the study group, patients were received docetaxel (made in Beijing) 75 mg/m(2) in one hour plus cisplatin 70 mg/m(2); while in the control group, docetaxel (made in Jiangsu) 75 mg/m(2) plus cisplatin 70 mg/m(2) were administrated. Treatment in the two groups was repeated every 3 weeks. All patients had to receive at least two cycles of chemotherapy.


RESULTS
The objective responses in the study and control group were 28.95% and 27.03% respectively, with no statistical difference (P>0.5). Common toxicities of docetaxel (made in Beijing) were grade II-III myelosuppression, grade I-II transaminase elevation, alopecia and hypodynamia.


CONCLUSIONS
Docetaxel (made in Beijing) is an effective chemotherapy drug in advanced NSCLC treatment, which has the similar efficacy and toxicity to docetaxel (made in Jiangsu).
Cao
Ye
Y
State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, P. R. China.
Wang
Zhi-Qiang
ZQ
Guo
Ying
Y
Feng
Feng-Yi
FY
Hu
Xiao-Hua
XH
Xiong
Jian-Ping
JP
Tang
Gui-Di
GD
Guan
Zhong-Zhen
ZZ
Zhang
Li
L
D000293:Adolescent; D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D000077143:Docetaxel; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009367:Neoplasm Staging; D012074:Remission Induction; D043823:Taxoids / Q000008:administration & dosage* / Q000009:adverse effects; D055815:Young Adult
D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin